)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Microba Life Sciences
Microba Life Sciences (MAP) investor relations material
Microba Life Sciences H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary30 Aug, 2026
Executive summary
Completed transition to a focused core testing business, with core testing revenue up 92% to $8.6M, now the majority of group revenue.
Total revenue declined 6% to $14.8M due to planned phase-out of legacy products; continuing product revenue grew 53% to $12.7M.
Statutory loss after tax increased 39% to $20.7M, impacted by non-cash and non-recurring items; underlying loss improved 11% to $18.8M.
No dividends declared or paid for the year.
Financial highlights
Gross margin held steady at 47.6% (FY25: 47.5%).
Operating expenses reduced 7% to $29.9M, reflecting cost management and restructuring.
Cash at 30 June 2026 was $7.9M, down from $11.7M in FY25.
Net tangible assets per share fell to 0.18 cents (FY25: 1.57 cents).
Receipts from customers were $15.6M; net operating cash outflow was $12.4M.
Outlook and guidance
FY27 priorities: launch Microba GI Navigator, grow core testing volumes in Australia and UK, realise full benefit of $7M annual cost reduction, and advance therapeutics partnering.
Targeting whole-company cashflow break-even on a run-rate basis in calendar year 2027.
Forward financials assume operating expenditure grows below revenue, continued clinical adoption, and sufficient capital.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Microba Life Sciences
- Core testing revenue up 92% YoY, with new products and cost cuts driving path to break-even.MAP
Q4 2026 - Cash flow breakeven targeted for CY2027, supported by strong growth and operational efficiencies.MAPInvestor update
- Core testing revenue up 99% YoY, with record test volumes and new product launches ahead.MAPQ3 2026
- Core test sales surged 113% year-over-year, driving growth amid legacy product exit and cost reductions.MAPH1 2026
- Revenue up 147% and net loss halved as testing sales accelerate and strategic growth initiatives advance.MAPH1 2025
- Core testing volumes up 90% YoY, with 123% revenue growth and cost reductions driving FY26 outlook.MAPQ2 2026
- Record core test sales and 30% revenue growth position the business for FY26 break-even.MAPQ4 2025
- Diagnostic test growth, clinical breakthroughs, and global expansion drive strong FY25 outlook.MAPQ3 2025
- Q2 FY25 revenue up 102% YoY, MetaXplore sales up 195%, and $17.3m cash supports growth.MAPQ2 2025
Next Microba Life Sciences earnings date
Q1 20273 Nov, 2026
Microba Life Sciences
Next Microba Life Sciences earnings date
Q1 20273 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Microba Life Sciences Limited is a biotechnology company specializing in microbiome analysis and therapeutics. The company provides advanced gut microbiome testing services using metagenomic sequencing technology to offer insights into human health. Microba also conducts research and development to discover and develop microbiome-based therapeutics targeting conditions such as inflammatory and metabolic diseases. The company is headquartered in Brisbane, Australia, and its shares are listed on the ASX.